Mary Kay Inc. Joins Forces with the Equal Rights Trust to Pioneer Research on Gender Inequality in Algorithms and Artificial Intelligence
4.10.2021 11:00:00 EEST | Business Wire | Press release
Mary Kay Inc., a global leader in women’s empowerment, today announced a partnership with the Equal Rights Trust (ERT), an organization whose mission is to eliminate all forms of discrimination and ensure everyone can participate in society on an equal basis. Established in 2007, the Trust works in partnership to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. will help ERT jumpstart an innovative field of research on artificial intelligence and algorithms through a gender-based lens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005308/en/
Equal Rights Trust logo (Graphic: Mary Kay Inc.)
“As a company founded on the mission to enrich the lives of women everywhere, Mary Kay is constantly on the lookout for organizations we can partner with to make an impact for gender equality globally,” said Julia Simon, Chief Legal Officer and Chief Diversity Officer of Mary Kay Inc. “We’re excited to support Equal Rights Trust on their work to help advance equality by design and beyond forge a way forward to collaborations with the private sector. Our work with ERT is specifically focused on framing the new landscape of artificial intelligence and gender equality, a growing concern in the digital age.”
Mary Kay’s support to the ERT will pioneer a new field of research on the discriminatory impact of algorithmic systems. ERT has developed and promoted models of equality impact assessment, advocating an “equality by design” approach in public and private decision making as a means to ensure non-discrimination and equality of participation. An immediate priority is to launch an initiative to establish and address the emerging discriminatory impacts of algorithmic decision-making, specifically as it relates to gender.
“The use of algorithms and artificial intelligence is spreading,” said Ariane Adam, Deputy Director of the Equal Rights Trust. “These technologies are rapidly becoming essential parts of the analytical, communication, and even legal infrastructure for our societies. Despite the global proliferation of such systems, we are only just beginning to understand the flaws, limitations, and boundaries of algorithmic decision making, especially in terms of discrimination. We’re pleased to partner with Mary Kay to shine light on the potentially discriminatory impacts of using such technologies, in particular for women.”
The delivery of the initiative can be broken into three phases:
- Phase 1: research on emerging discriminatory impacts of the use of algorithmic-decision making in the areas of employment, access to loans, and access to housing, including a focus on the impact of women as a group particularly exposed to discrimination in these contexts.
- Phase 2: engagement with a wide-range of actors to develop advocacy strategies to call for an equality by design approach in the design, development, roll-out and monitoring of AI technologies.
- Phase 3: engaging with international, regional and national actors to set standards mandating an equality by design approach.
The partnership with the Equal Rights Trust is just the latest initiative supported by Mary Kay in 2021 to advocate for gender equality everywhere. For nearly 60 years, Mary Kay has been committed to empowering women and their families by partnering with organizations from around the world.
ABOUT EQUAL RIGHTS TRUST
The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this mission, it works in partnership with equality defenders – civil society organizations (CSOs), lawyers, government representatives, and others committed to using law to create an equal world – providing them with the technical, strategic and practical support they need to work for the adoption and implementation of comprehensive equality laws. Since 2007, it has supported equality defenders in almost 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005308/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
